New York-based biopharmaceutical developer MindMed announced last week that it has dosed the first patient in a clinical trial of LSD as a treatment for generalized anxiety disorder.
New York-based biopharmaceutical developer MindMed announced last week that it has dosed the first patient in a clinical trial of LSD as a treatment for generalized anxiety disorder.